The Duhring chamber assay for corticosteroid atrophy

Area of Science:

• Dermatology
• Pharmacology

Background:

• Topical corticosteroids are widely used for inflammatory skin conditions.
• Assessing their potential for skin thinning (atrophogenicity) is crucial for safe and effective use.

Purpose of the Study:

• To introduce and validate a novel human model for evaluating the atrophogenicity of topical corticosteroids.
• To compare the atrophogenicity of different corticosteroid formulations and potencies.

Main Methods:

• Normal forearm skin of human volunteers was treated with formulated corticosteroids (creams, ointments) under occlusion for 3 weeks using Duhring chambers.
• Skin atrophy and telangiectasia were assessed using a stereomicroscope on a validated five-point scale.

Main Results:

• A strong correlation was observed between skin atrophy and telangiectasia.
• Significant differences in atrophogenicity were found among corticosteroids, from none (hydrocortisone) to very severe (clobetasol propionate).
• A dose-response relationship was evident concerning exposure time and corticosteroid concentration, and vehicle type (ointments vs. creams) influenced outcomes.

Conclusions:

• The proposed human model is a reliable tool for assessing topical corticosteroid atrophogenicity.
• Corticosteroid potency, concentration, exposure duration, and vehicle formulation all play a role in the degree of skin thinning and telangiectasia observed.